Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD)

SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1

Ana Cuenda, J.B. Rouse, Yair N. Doza et al. · FEBS Letters · 1995 · 2.1K citations

Life Sciences, Molecular Biology, Pharmacology +14

A small molecule–kinase interaction map for clinical kinase inhibitors

Miles A. Fabian, William Biggs, Daniel K. Treiber et al. · Nature Biotechnology · 2005 · 1.9K citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +12

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

Christopher Pargellis, Liang Tong, Laurie Churchill et al. · Nature Structural Biology · 2002 · 834 citations · Full text

Life Sciences, Immunology, Molecular Biology +15

Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis

Georg Schett, M Tohidast-Akrad, Josef S. Smolen et al. · Arthritis & Rheumatism · 2000 · 375 citations

Medicine, Immunology, Pathobiology +17

Pyrazole Urea-Based Inhibitors of p38 MAP Kinase:  From Lead Compound to Clinical Candidate

John R. Regan, Steffen Breitfelder, Pier F. Cirillo et al. · Journal of Medicinal Chemistry · 2002 · 350 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17